Status:
COMPLETED
Extension to a Study on the Efficacy and Safety of Vildagliptin in Combination With Insulin in Patients With Type 2 Diabetes
Lead Sponsor:
Novartis
Conditions:
Diabetes Mellitus, Type 2
Eligibility:
All Genders
18-80 years
Phase:
PHASE3
Brief Summary
Many people with type 2 diabetes cannot maintain their target blood glucose levels on a single therapy. This is a 28-week extension to a study to assess the safety and effectiveness of vildagliptin, a...
Eligibility Criteria
Inclusion
- Only patients successfully completing study CLAF237A2311 are eligible
- Written informed consent
- Ability to comply with all study requirements
Exclusion
- Premature discontinuation from CLAF237A2311
- Other protocol-defined exclusion criteria may apply
Key Trial Info
Start Date :
January 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 1 2006
Estimated Enrollment :
179 Patients enrolled
Trial Details
Trial ID
NCT00138606
Start Date
January 1 2005
End Date
January 1 2006
Last Update
November 18 2016
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Novartis Pharmaceuticals
East Hanover, New Jersey, United States, 07936
2
Novartis Investigative Site
Investigative Centers, Germany